NordiTest E 300mg/ml 10ml Vial by Nordi Pharma

Usage

1. Confirm your SARM selection and map its suppression profile before choosing the NordiTest E weekly dose — mild SARMs (Ostarine) allow a 200mg/week anchor; potent SARMs (LGD-4033, RAD-140) typically require 250–300mg/week to offset their stronger suppressive effect.
2. Draw NordiTest E with an 18–21 gauge needle to exploit the 300mg/ml oil concentration efficiently; minimise dead-space loss by using luer-lock syringes throughout.
3. Administer NordiTest E intramuscularly (gluteus, vastus lateralis, or dorsogluteal) on a Monday/Thursday schedule to maintain stable inter-dose serum levels across the full week.
4. Administer your SARM orally on its own daily or alternate-day schedule independently — NordiTest E injection days and SARM oral doses do not need to be synchronised.
5. At weeks four and eight, draw bloodwork measuring serum testosterone (LC-MS/MS preferred), LH, FSH, oestradiol, haematocrit, HDL, and liver enzymes; adjust NordiTest E volume based on results rather than theoretical targets.
6. Taper NordiTest E in the final two to four weeks of the cycle ahead of PCT; keep the vial stored at 15–25°C, use a fresh sterile needle for every draw, and dispose of the vial no later than 28 days after first puncture.

Warnings

Frequently asked questions

Can Testosterone Enanthate be combined with SARMs in the same cycle?

Yes — testosterone enanthate is frequently used as a full-agonist base alongside SARMs such as LGD-4033, RAD-140, or Ostarine. SARMs suppress endogenous testosterone production by 30–60% in controlled assessments; adding NordiTest E at 200–300mg weekly prevents the androgenic deficit that would otherwise blunt muscle retention and libido during the SARM run.

Which SARM combinations are most commonly paired with Testosterone Enanthate 300mg/ml?

LGD-4033 (Ligandrol) and RAD-140 (Testolone) are the most documented pairings in community and early clinical literature. LGD-4033 targets lean mass accumulation with high muscle selectivity, while RAD-140 shows the highest anabolic-to-androgenic ratio among characterised SARMs. Both benefit from a testosterone anchor that covers systemic androgenic functions the SARM cannot fully replicate.

What monitoring should be done when stacking NordiTest E with a SARM?

Serum total testosterone, LH, FSH, and oestradiol should be measured at baseline and again at weeks four and eight using immunoassay or LC-MS/MS methods. Haematocrit, lipid panel (HDL suppression is documented for both SARMs and exogenous testosterone), and liver enzymes should be included. Adjust NordiTest E dose based on bloodwork rather than theoretical targets.

How do I draw an accurate dose from a 300mg/ml vial using a standard syringe?

A standard 1ml syringe graduated in 0.1ml increments allows accurate measurement of 200mg (0.67ml) or 150mg (0.5ml) from NordiTest E. For sub-0.5ml draws, a 1ml syringe with 0.01ml graduation markings provides the resolution needed for precise micro-volume control. Always draw with a larger-gauge needle and switch to a finer needle for injection to reduce dead-space loss.

How should NordiTest E be stored after the vial is first opened?

Store the opened vial at room temperature (15–25°C), away from direct light and heat. Do not refrigerate an opened multi-dose vial, as cold temperatures increase oil viscosity and may cause crystallisation at the injection site. Use a fresh sterile needle for every draw, and discard the vial 28 days after first puncture regardless of remaining volume to maintain microbiological integrity. (2) angle_used

Manufacturer

Nordi Pharma subjects every batch of NordiTest E to a validated aseptic manufacturing process built around Grade A laminar-flow filling environments, where vial filling, stoppering, and crimping are executed under continuous active air-particle monitoring that meets pharmacopoeial sterility-assurance requirements. Environmental monitoring data — including viable and non-viable particle counts — are reviewed against pre-defined alert and action limits before any batch proceeds to the release stage. Finished vials undergo LAL endotoxin assay testing to confirm bacterial endotoxin load falls within pharmacopoeial acceptance criteria, and HPLC content-assay results are retained as part of each lot's certificate of analysis, ensuring that the 300mg/ml specification declared on the label reflects the actual concentration in solution. This aseptic quality framework is integral to NordiTest E's suitability for multi-injection protocols such as SARM co-administration cycles, where cumulative injection count over a 10–14 week period makes sterility consistency — not just nominal concentration — a primary product attribute.